Molecular basis of inhibition of the amino acid transporter B AT1 (SLC6A19)

Junyang Xu,Ziwei Hu,Lu Dai,Aditya Yadav,Yashan Jiang,Angelika Bröer,Michael Gardiner,Malcolm McLeod,Renhong Yan,Stefan Bröer

DOI: https://doi.org/10.1101/2024.02.18.580905

2024-02-18

Abstract:The epithelial neutral amino acid transporter B AT1 (SLC6A19) is the major transporter for the absorption of neutral amino acids in the intestine and their reabsorption in the kidney. Mouse models have demonstrated that lack of B AT1 can normalize elevated plasma amino acids in rare disorders of amino acid metabolism such as phenylketonuria and urea-cycle disorders. This discovery has resulted in a quest to identify high-affinity selective inhibitors of B AT1 for the treatment of disorders of amino acid metabolism. Here we employed a medicinal chemistry approach to improve lead compounds that were identified in a previous high-throughput screen. This effort yielded a group of compounds that inhibited B AT1 with IC -values of 31-90 nM. High-resolution cryo-EM structures of B AT1 in the presence of two compounds from this series identified an allosteric binding site in the vestibule of the transporter. Mechanistically, binding of these inhibitors prevents a substantial movement of TM1 and TM6 that is required for the transporter to make a conformational change from an outward open state to the occluded state.

Biochemistry